"Severe neutropenia occurs in a small percentage of patients taking clozapine; however, neutropenia is associated with an ...
In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval ...
Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute ...
PharmaTher Holdings Ltd (TSE:PHRM) has released an update. PharmaTher Holdings Ltd. has secured a meeting with the FDA to address a complete ...
Opens in a new tab or window The FDA declined to grant full approval to obeticholic acid (Ocaliva) for treating primary ...
The U.S. Food and Drug Administration's ("FDA") new advisory committee on digital health is set to examine its approach for evaluating and ...
Braian Paiz, the alleged drug dealer of former One Direction member Liam Payne, has spoken up about their encounters. In an ...
As part of the process, the company will be conducting an ‘End-of-Phase 2’ meeting with the FDA later this month to get input from the agency on their proposed trial design. The study is ...
On November 12, 2024, the FDA granted the Meeting scheduled for November 29, 2024. Due to the U.S. Thanksgiving Holiday and scheduling conflicts of attendees from its CDMO partner, the Company has ...
SYDNEY - Kazia Therapeutics Limited (NASDAQ: KZIA), an Australian biotechnology firm, has secured a Type C meeting with the U.S. Food and Drug Administration (FDA) set for December 2024 to discuss ...
The malaria parasite may be gaining resistance against artemisinin, the drug most often used to try and save children with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback